Tumor necrosis factor α (TNF-α)-induced RANTES chemokine expression via activation of NF-κB and p38 MAP kinase: Roles of TNF-α in alcoholic liver diseases

Journal of Hepatology

Volumn 38, Issue 4, 2003, Pages 483-489

  Hirano, Fuminori ^a   Komura, Keiji ^a   Fukawa, Etsushi ^a   Makino, Isao ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Hepatocyte; MAP kinase; NF B; P38; RANTES; Tumor necrosis factor

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CALPHOSTIN C; CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RANTES; TUMOR NECROSIS FACTOR ALPHA; WORTMANNIN;

ALCOHOL LIVER DISEASE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 0037383455     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00456-7     Document Type: Article

References (44)

1. Scherlock S. Alcohol-related liver disease. Br Med Bull 1982;38:67-70.
2. Lieber CS, DeCarli LM, Sorrell MF. Experimental methods of ethanol administration. Hepatology 1989;10:501-510.
3. Hall PD. Pathological spectrum of alcoholic liver disease. Alcohol 1994;Suppl 2:303-313.
4. Lieber CS. Alcoholic liver injury: pathogenesis and therapy in 2001. Pathol Biol 2001;49:738-752.
5. McClain CJ, Cohen DA, Dinarello CA, Cannon JG, Shedlofsky SI, Kaplan AM. Serum interleukin-1 (IL-1) activity in alcoholic hepatitis. Life Sci 1986;39:1479-1485.
6. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-920.
7. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-274.
8. Daniluk J, Szuster-Ciesielska A, Drabko J, Kandefer-Szerszen M. Serum cytokine levels in alcohol-related liver cirrhosis. Alcohol 2001;23:29-34.
9. Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, et al. Plasma tumor necrosis factor α predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990;14:255-259.
10. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-276.
11. Menon KV, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001;76:1021-1029.
12. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988;2:72-74.
13. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349-351.
14. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669-671.
15. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity 1998;9:1-11.
16. Schall TJ. Biology of the RANTES/SIS cytokine family. Cytokine 1991;3:165-183.
17. Maltby J, Wright S, Bird G, Sheron N. Chemokine levels in human liver homogenates: associations between GROα and histopathological evidence of alcoholic hepatitis. Hepatology 1996;24:1156-1160.
18. Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, et al. Activation of nuclear factor κB and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology 1999;30:934-943.
19. Chedid A, Mendenhall CL, Moritz TE, French SW, Chen TS, Morgan TR, et al. Cell-mediated hepatic injury in alcoholic liver disease. Veterans Affairs Cooperative Study Group 275. Gastroenterology 1993;105:254-266.
20. Moriuchi H, Moriuchi M, Fauci AS. Nuclear factor-KB potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol 1997;158:3483-3491.
21. Hashimoto S, Gon Y, Asai Y, Asai Y, Machino T, Jibiki I, et al. p38 MAP kinase regulates RANTES production by TNF-α-stimulated human pulmonary vascular endothelial cells. Allergy 1999;54:1168-1172.
22. Hashimoto S, Matsumoto K, Gon Y, Maruoka S, Kujime K, Hayashi S, et al. p38 MAP kinase regulates TNFα-, IL-1α- and PAF-induced RANTES and GM-CSF production by human bronchial epithelial cells. Clin Exp Allergy 2000;30:48-55.
23. Machelon V, Nome F, Emilie D. Regulated on activation normal T expressed and secreted chemokine is induced by tumor necrosis factor-α in granulosa cells from human preovulatory follicle. J Clin Endocrinol Metab 2000;85:417-424.
24. Doi I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 1976;67:1-10.
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
26. Hirano F, Chung M, Tanaka H, Maruyama N, Makino I, Moore DD, et al. Alternative splicing variants of IκBβ establish differential NF-κB signal responsiveness in human cells. Mol Cell Biol 1998;18:2596-2607.
27. Hirano F, Kobayashi A, Hirano Y, Nomura Y, Fukawa E, Makino I. Bile acids regulate RANTES gene expression through its cognate NF-κB binding sites. Biochem Biophys Res Commun 2001;288:1095-1101.
28. Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM. Genomic organization and transcriptional regulation of the RANTES chemokine gene. J Immunol 1993;151:2601-2612.
29. Nelson PJ, Ortiz BD, Pattison JM, Krensky AM. Identification of a novel regulatory region critical for expression of the RANTES chemokine in activated T lymphocytes. J Immunol 1996;157:1139-1148.
30. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265:808-811.
31. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746.
32. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995;270:7420-7426.
33. Brinkman BM, Telliez JB, Schievella AR, Lin LL, Goldfeld AE. Engagement of tumor necrosis factor (TNF) receptor 1 leads to ATF-2- and p38 mitogen-activated protein kinase-dependent TNF-α gene expression. J Biol Chem 1999;274:30882-30886.
34. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-κB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 1998;273:3285-3290.
35. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression. J Biol Chem 1999;274:27161-27167.
36. Wajant H, Grell M, Scheurich P. TNF receptor associated factors in cytokine signaling. Cytokine Growth Factor Rev 1999;10:15-26
37. Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 2000;60:1185-1195.
38. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002;296:1634-1635.
39. Cao Z, Tanaka M, Regnier C, Rothe M, Yamit-hezi A, Woronicz JD, et al. NF-κB activation by tumor necrosis factor and interleukin-1. Cold Spring Harbor Symp Quant Biol 1999;64:473-483.
40. Goebeler M, Gillitzer R, Kilian K, Utzel K, Brocker EB, Rapp UR, et al. Multiple signaling pathways regulate NF-κB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood 2001;97:46-55.
41. Craig R, Larkin A, Mingo AM, Thuerauf DJ, Andrews C, McDonough PM, et al. p38 MAPK and NF-κB collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 2000;275:23814-23824.
42. Chae HJ, Chae SW, Chin HY, Bang BG, Cho SB, Han KS, et al. The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts. Bone 2001;28:45-53.
43. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997;26:143-146.
44. Cao Q, Batey RG, Pang GT, Clancy RL. Ethanol-altered liver associated T cells mediated liver injury in rats administered concanavalin (Con A) or lipopolysaccharide (LPS). Alcohol Clin Exp Res 1999;23:1660-1667.